Clinical Study of ICP-192 in Solid Tumors Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE1/PHASE2

Total Enrollment

56 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-12-19

Study Completion Date

2024-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Open-label, non-randomized, Phase I/IIa, dose-escalating, dose-extension, first-in-man study.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Phase I/II Clinical Trial of ICP-723 in the Treatment of Advanced Solid Tumors

NCT04685226

Solid Tumors

RECRUITING PHASE1/PHASE2

Evaluation of ICP-B794 in Patients With Advanced Solid Tumors

NCT07136558

Advanced Solid Tumors

NOT_YET_RECRUITING PHASE1

A Clinical Trial of ICP-192 in Treated Patients With Advanced Solid Tumors With FGF/FGFR Gene Alterations

NCT05372120

Advanced Solid Tumor

UNKNOWN PHASE2

A Study of ICP-189 and ICP-189 in Combination With Anti-PD-1 Monoclonal Antibody in Patients With Advanced Solid Tumors

NCT05370755

Patients With Advanced Solid Tumors

NOT_YET_RECRUITING PHASE1

Phase I/II Study of IPG1094 in Advanced Solid Tumors Patients

NCT06212076

Solid Tumor

RECRUITING PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study consisted of a screening period, a treatment period with 21 days of repeated treatment per cycle (duration treatment with ICP-192), and a follow-up period (28 days after last dose). The recruited patients receive a single dose on day 1, then after a 3-day washout period, repeated dosing will be followed. The starting dose is 2 mg, QD, and dose escalation will follow accelerated titration and modified 3+3 dose-finding schema. The dose-limiting toxicity (DLT) assessment period consisted of Cycle 0 (single dose and washout period) and Cycle 1 (21-day cycle).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Solid Tumor

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

ICP-192

The initial dose of ICP-192 is 2 mg, QD, and dose escalation schedule may be modified based on the safety and PK from the previous dose. Tentatively seven dose levels will be evaluated.

Group Type EXPERIMENTAL

ICP-192

Intervention Type DRUG

Drug: ICP-192 Dose levels will be escalated following accelerated titration and modified "3+3" dose escalation scheme,

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ICP-192

Drug: ICP-192 Dose levels will be escalated following accelerated titration and modified "3+3" dose escalation scheme,

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. An unresectable or metastatic advanced malignant solid tumor confirmed by histopathology that has failed to respond to known treatment or has recurred;Subjects who progress under standard treatment, are intolerant to standard treatment, or do not have standard treatment (dose escalation phase)
2. Tissue or cell pathology confirmed unresectable, recurrent or metastatic (AJCC version 8 TNM staging IV (2017), biliary tract malignant tumor, or intolerance to first-line chemotherapy failure (twice (defined as reduction still cannot tolerate) first-line chemotherapy, neoadjuvant/progress/adjuvant chemotherapy after 6 months recurrence can be selected (dose extension stage); - At least one evaluable disease according to RECIST1.1
3. FGFR2 translocation/fusion has been reported or FGFR2 translocation/fusion has been detected in central laboratory (dose extension phase);
4. Age ≥18 and ≤75
5. There is at least one evaluable lesion according to RECIST1.1 criteria
6. ECOG strength score is 0-1 (dose escalation stage), and ECOG strength score is 0-2 (dose expansion stage).
7. The expected survival time is more than 3 months
8. The organ function level must meet the following requirements (subject to the upper limit of normal value in the clinical trial center):

A) bone marrow: absolute count of neutrophils (ANC)≥1.5\*109/L (1500/mm3), platelet ≥75\*109/L, hemoglobin ≥9g/dL; B) coagulation function: international standardized ratio of prothrombin time and partial thrombin time \<1.5 times the upper limit of normal value; C) liver: serum bilirubin ≤1.5 times the upper limit of normal value (tumor involvement in the liver ≤2.5 times the upper limit of normal value), aspartic aminotransferase (AST) and alanine aminotransferase (ALT)≤3 times the upper limit of normal value (AST and ALT≤5 times the upper limit of normal value in the case of liver metastasis); D) serum creatinine ≤1.5 times the upper limit of normal value, or creatinine clearance ≥70mL/min (calculated according to the Cockroft-gult formula).
9. Volunteer to enroll and sign informed consent to follow the treatment protocol and visit plan.

Exclusion Criteria

* Previous treatment with FGFR small molecule inhibitors or antibody drugs.
* Anti-cancer therapy, such as chemotherapy (except for oral fluorouracil), immunotherapy, hormonal, targeted therapy, or investigational agents within four weeks of the first dose of ICP-192, oral fluorouracil agents within two weeks of the first dose of ICP-192.
* Major surgery within 6 weeks of the first dose of ICP-192.
* Blood phosphate persistently above ULN with intervene therapy within two weeks of the first dose of ICP-192.
* Significant GI disorder(s) that could interfere with the absorption, metabolism, or excretion of ICP-192.
* Central nervous system (CNS) metastasis
* Current clinically significant cardiovascular disease including:
* Any class 3 or 4 cardiac disease such as arrhythmia, congestive heart failure or myocardial infarction defined by the New York Heart Association Functional Classification, or left ventricular ejection fraction (LVEF) \< 50%, Primary cardiomyopathy, clinical significant QTc prolong history or QTc\>470ms (female) QTc\>450ms (male)
* Known active bleeding within 2 months of screening or 6 months of bleeding history.
* According to the investigator's judgement, there are evidences of a serious or uncontrollable systemic disease (such as unstable or uncompensated respiratory, liver or kidney disease); or any unstable systemic disease (including active clinically serious infections, uncontrolled hypertension, liver and kidney or metabolic diseases)
* History of interstitial pneumonia, deep vein thrombosis, pulmonary embolism. Stroke or intracranial hemorrhage within 6 months before the first dose of ICP-192.
* History of organ transplantation and allogeneic hematopoietic stem cell transplantation.
* Any corneal or retinal abnormalities that may increase ocular toxicity, including but not limited to:
* History of central serous retinopathy (CSR) or retinal vein occlusion (RVO) disease or has related diseases;
* Active age-related macular degeneration (AMD);
* Diabetic retinopathy with macular edema;
* Uncontrollable glaucoma;
* Keratonosus, such as Keratitis, keratoconjunctivitis, keratopathy, corneal wear, inflammation or ulceration.
* Known active infection with HBV, HCV or HIV or any uncontrolled active systemic infection
* Any toxicities must recover to ≤ Grade 1 from prior anti-cancer therapy (excluding alopecia, nausea and vomiting).
* Lactating or pregnant women, or women who will not use contraception during the study and for 180 days after the last dose of study drug if sexually active and able to bear children.
* Investigators believe that the patients are not eligible for enrollment for the other reasons.

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jin Li, PhD

Role: PRINCIPAL_INVESTIGATOR

Shanghai East Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.